`ÿ
`
` ! " #"ÿ%""#&"' (ÿ)*%ÿ%++#,%-ÿ#)ÿ .- %/ÿ0%)-12 ' +34ÿ1"5 '31#"ÿ)#
`
`

 ÿÿÿ
`ÿÿÿ
`
`6%'&-%ÿ * 6%ÿ)#--#71"!ÿ' "3%-ÿ 31"%-ÿ, 1"ÿ#''-&(1#"
`899:;<=ÿ=>:>ÿ
`>ÿÿÿ?9=@A@B ?ÿCCÿ9DE FEÿG H
`BIAÿJE>ÿK=88Lÿ9M=Nÿ
`FOP
`EEFHEOÿ
`G
`ÿ
`GÿQ>>ÿRFFOÿEOÿ HDÿ8OBEBA
` 
`BFEÿKR8NÿGAÿ FSOÿ:T8ÿKUB

 
`NÿJEV
`BFEÿWF ÿ
`G
`
` 
`E
`ÿFWÿHI ÿOÿWFIIF@BEDÿXE
` Iÿ9
`BEIÿYBEÿ;IHABFEÿKX9Y;N>ÿÿGÿ FEOOÿOFAÿWF ÿ:T8ÿBA
`‘
`ÿBIIBD AÿKDNÿS Pÿ[ÿ@AÿKFE
`GIPN>
`\GBAÿAFEOÿQ>>ÿ FSIÿWF ÿ:T8ÿ FSBOAÿ GPABBEAÿEOÿ 
`BE
`Aÿ@B
`GÿÿE@ÿ
` 
`E
`ÿF
`BFEÿWF ÿ
`Gÿ
` 
`E
`
`FWÿHI ÿOÿWFIIF@BEDÿX9Y;\ÿA
`
`OÿMF Dÿ>ÿ:EF FHIFAÿ>>ÿG>>ÿXGBWÿBE
`B]ÿ;^ ÿFWÿ9DE FE
`EOÿ ABOE
`ÿFWÿ9DE FEÿT

F 
`F BA>ÿ\AOÿH FEÿ
`Gÿ BSF
`IÿGAÿ_ÿA
`HOPÿ AHI
`Aÿ:T8ÿGAÿ

EÿAGF@Eÿ
`F
`ABDEB]E
`IPÿB FSÿSBAHIÿFH
`FAÿBEÿÿOBAAÿG 
` B`Oÿ

PÿGBDGÿYMRÿISIA>ÿÿ<ÿ
`GEÿ
`Gÿ 
`BE
`AÿEO
`
`IBEBIÿBESA
`BD
`F Aÿ@GFÿ 
`BB 
`OÿBEÿFH ÿIBEBIÿA
`HOBAÿ
`GÿR8ÿEOÿ
`Gÿ9DE FEÿ IFPAÿ@GFÿGI O
`ÿ
`GBAÿOPÿ FAAB

I>\ÿÿ
`Gÿ FSIÿFWÿ:T8ÿWF ÿHI ÿOÿWFIIF@BEDÿX9Y;ÿ@Aÿ

AOÿFEÿO
`ÿW Fÿ
`GÿGAÿ_ÿX;9=JXQÿEO
`M8TJT;ÿA
`HOBA>ÿÿJEÿ

F
`GÿA
`HOBAÿ
`Gÿ B Pÿ^PÿEO FBE
`ÿ@Aÿ
`Gÿ F F
`BFEÿFWÿ 
`BE
`Aÿ@GFÿDBEOÿ
`ÿIA
`
`aÿI
`
` AÿFWÿA
`ÿXF 
`OÿYBAHIÿ8HB
`PÿKXY8Nÿ
`ÿ[ÿ@AÿF  Oÿ
`Fÿ

AIBEÿAÿAH Oÿ

Pÿ9>ÿÿ9AHI
`A
`WF ÿ
`Gÿ:T8ÿÿDÿFE
`GIPÿD FH ÿ@ ÿAH  BF ÿ
`Fÿ
`GFAÿWF ÿ
`GÿAGÿFE
` FIÿD FH ÿWF ÿ
`Gÿ B PÿEO FBE
`>
`:T8ÿBAÿFE
` BEOB
`OÿBEÿ 
`BE
`Aÿ@B
`GÿFHI ÿF ÿ  BFHI ÿBEW
`BFEAÿ
`BSÿBE
` FHI ÿBEU
`BFEÿF ÿEF@E
`GP  AEAB
`BSB
`Pÿ
`FÿUB

 
`ÿF ÿ
`FÿEPÿFWÿ
`GÿbB BE
`AÿBEÿ:T8>
`9AHI
`AÿW Fÿ@ÿ[ÿ
`G FHDGÿaÿFWÿ
`GÿX;9=JXQÿEOÿM8TJT;ÿA
`HOBAÿGSÿEF
`ÿP
`ÿ

Eÿ SB@Oÿ

Pÿ
`GÿR8>
`cdefgÿijkicÿlmnodpqrpsgtÿuvwprgoevÿxeqÿuvgqmyogqpmzÿuvwprgoevÿ
`YAHI ÿEOF
`GIBIÿM F@
`GÿR
`F ÿKYMRNÿBAÿÿE
`H IIPÿFH BEDÿ F
`BEÿBEÿ
`Gÿ

FOP>ÿÿJ
`AÿEF Iÿ FIÿBEÿÿGI
`GP
`’
`F DEBAÿBAÿ
`Fÿ
` BDD ÿWF 
`BFEÿFWÿE@ÿ

IFFOÿSAAIAÿKEDBFDEABANÿAH F
`BEDÿ
`GÿD F@
`GÿFWÿ
`Gÿ

FOP{Aÿ
`BAAHAÿEO
`F DEA>ÿÿ|F@S ÿBEÿ
`BEÿOBAAAÿAHGÿAÿ@
`ÿDC I
`OÿHI ÿODE 
`BFEÿB
`ÿBAÿIAFÿAAFB
`Oÿ@B
`Gÿ
`G
`D F@
`GÿFWÿ

EF IÿE@ÿ

IFFOÿSAAIAÿBEÿ
`GÿPÿ@GBGÿbGB

B
`ÿ

EF IÿBE AOÿ  

BIB
`Pÿ
`G
`ÿIOAÿ
`F
`O>ÿ BEDÿEOÿIFAAÿFWÿ]EC AFIH
`BFEÿE
` IÿSBABFEÿFW
`Eÿ AHI
`A>ÿJEÿXE
` Iÿ9
`BEIÿYBEÿ;IHABFEÿKX9Y;Nÿ
`

IFDÿFH AÿBEÿ
`GÿBEÿ

IFFOÿSAAIÿ
`G
`ÿ
` EA F
`AÿOFbPDE
`Oÿ

IFFOÿ@PÿW Fÿ
`Gÿ 
`BE>ÿÿYMRÿISIAÿ 
`
`IS
`OÿBEÿ A FEAÿFE
` B

H
`BEDÿ
`FÿHI ÿO>
`:T8ÿBAÿÿ F

BEE
`ÿWHABFEÿ F
`BEÿFEABA
`BEDÿFWÿ F
`BFEAÿFWÿGHEÿYMRÿ 
`F AÿÿEOÿÿb
` IIHI
`OFBEAÿWHAOÿ
`Fÿ
`GÿRÿ F
`BFEÿFWÿGHEÿJDMÿEOÿWF HI
`OÿAÿEÿBAFCFAF
`BÿAFIH
`BFEÿWF ÿBE
` SB
` I
`OBEBA
` 
`BFE>ÿÿ:T8ÿ
`AÿAÿÿAFIH

IÿOFPÿ 
`F ÿ
`G
`ÿ

BEOAÿYMRC8ÿEOÿ IE
`IÿD F@
`GÿW
`F ÿKIMRNÿEO
`
`G 

PÿEÿBEGB

B
`ÿ
`Gÿ

BEOBEDÿEOÿ
`BS
`BFEÿFWÿ
`GAÿFDE
`ÿYMRÿ 
`F A>ÿÿ:T8ÿBAÿA BIIPÿ H B]OÿEO
`FE
`BEAÿBAFCFAF
`Bÿ

HWW ÿFEE
` 
`BFEAÿIIF@BEDÿWF ÿBEV
`BFEÿBE
`Fÿ
`GÿP>
`cdefgÿg}pÿ~}mpÿ€ÿ~qeqm‚ÿƒog}ÿijkicÿlmnodpqrpsgtÿuvwprgoevÿovÿ„mrfzmqÿi…p‚mÿxezzeƒovÿ†‡ˆ‰
`’
`GÿAW
`PÿEOÿ^PÿFWÿ:T8ÿBEÿ
`Gÿ
` 
`E
`ÿFWÿHI ÿOÿWFIIF@BEDÿX9Y;ÿ@ ÿAAAAOÿBEÿ
`@F
` EOFB`OÿHI
`BCE
` ÿOFH

ICAOÿAGCFE
` FIIOÿA
`HOBAÿX;9=JXQÿKXFE
` FIIOÿGAÿ_ÿSIH
`BFEÿFW
`9 
`OÿBE
` SB
` IÿOBEBA
` 
`BFEÿFWÿYMRÿ  CPÿJEÿXE
` Iÿ 
`BEIÿSBEÿFIHABFEÿQ
`BIB
`PÿEOÿW
`PNÿEO
`M8TJT;ÿKME Iÿ8AAAAE
`ÿTBB
`BEDÿJE]I
` 
`BFEÿFWÿbHO
`AÿBEÿE
` Iÿ 
`BEIÿSBEÿ;IHABFEÿ@B
`Gÿ:T8N>
`8ÿ
`F
`IÿFWÿ_aŠÿ 
`BE
`Aÿ@ ÿ
` 
`OÿEOÿSIH

IÿWF ÿ^PÿKÿ@B
`Gÿ:T8NÿBEÿX;9=JXQÿEOÿM8TJT;>ÿJE
`

F
`GÿA
`HOBAÿ 
`BE
`Aÿ@ ÿ EOFIPÿAABDEOÿBEÿÿ_ÿ 
`BFÿ
`FÿB
`G ÿÿDÿ:T8ÿOBEBA
` OÿS Pÿ[ÿ@AÿKL[N
`F ÿAGÿBEV
`BFEAÿKFE
` FIÿD FH NÿOBEBA
` OÿS Pÿ[ÿ@AÿWF ÿÿ
`F
`IÿFWÿ‹ÿBEV
`BFEA>ÿÿ8W
` ÿ‹ÿFE
`GIPÿBEV
`BFEA
` 
`BE
`AÿFE
`BEHOÿ
`Fÿ BSÿ:T8ÿ
` 
`E
`ÿOH BEDÿ@Aÿ[ÿ
`FÿaÿFEIPÿBWÿ
`GPÿ
`ÿ CA B]Oÿ 
` 
`E
`
`
` B
` BÿK9=Nÿb
`ÿWF ÿ 
`BE
`AÿBEÿ
`GÿAGÿFE
` FIÿD FH ÿBEÿ
`GÿM8TJT;ÿA
`HOPÿ@GFÿFE
`BEHOÿ
`Fÿ BSÿAG
`BEV
`BFEAÿ
`G FHDGÿ@ÿa>ÿÿ
`BE
`Aÿ EDOÿBEÿDÿW Fÿÿ
`FÿŠŒÿP Aÿ@B
`GÿÿEÿFWÿ‹[ÿP A>
`JEÿ
`GÿX;9=JXQÿA
`HOPÿW
` ÿABbÿFE
`GAÿa‹ÿFWÿ 
`BE
`Aÿ BSBEDÿ:T8ÿÿDÿFE
`GIPÿDBEOÿ
`ÿIA
`ÿaÿI
`
` A
`FWÿA
`ÿXF 
`OÿYBAHIÿ8HB
`PÿKXY8NÿW Fÿ

AIBEÿAÿAH Oÿ

Pÿ9ÿF  Oÿ
`FÿÿFWÿ 
`BE
`Aÿ BSBED
`AGÿBEV
`BFEAÿK ÿŽ‹ÿ>Nÿ
`Gÿ B PÿEO FBE
`ÿFWÿ
`GÿA
`HOP>ÿÿ
`BE
`Aÿ BSBEDÿ:T8ÿÿDÿFE
`GIPÿDBEOÿFE
`S Dÿ>_ÿI
`
` AÿFWÿSBABFEÿF  Oÿ
`FÿÿEÿIFAAÿFWÿ[>ÿI
`
` Aÿ@B
`GÿAGÿFE
` FIÿBEV
`BFEAÿK ÿŽ‹ÿ>Nÿ
`AFEO PÿEO FBE
`>ÿÿ
`
` 
`
`Exhibit 2252
`Page 01 of 03
`
`

`

` ÿÿ
` 

ÿÿÿÿÿÿÿÿ ÿ

!

`ÿ"ÿ ÿ#ÿÿÿ$ÿÿÿ 
`ÿ#ÿ%&ÿ#ÿÿ'()
`ÿÿ*#ÿÿÿ""ÿÿÿ ÿÿ+ÿ,ÿ-.ÿ/%0
` ÿÿÿÿÿÿÿÿ/ÿÿ2ÿ ÿ

!

`ÿ"ÿ ÿ#ÿ ÿÿ ÿ%3/
`#ÿÿÿÿÿÿÿ ÿÿ4/4ÿ#ÿ5ÿÿ#ÿ+ÿ,ÿ-.ÿ/%0ÿÿ
`/
`6#ÿÿ57ÿ"8ÿ ÿ&"ÿÿÿ( 2

69 (:;ÿÿ
` 

ÿÿÿÿÿ*ÿ5ÿ*ÿÿ<=
`/
`>?@ABCDECÿ@BGHIB>J>EKÿ>ELAB?DC>AEÿLABÿGMNGDÿOPQRSTUVTWXYÿ>EZGIC>AEÿ
` ÿÿ:ÿ;ÿ

!

`ÿ,[*0ÿ +ÿÿÿÿÿÿÿÿ5ÿ#ÿ,\0
`r
`
` ]#ÿ^#ÿ= ÿ,
`^=0/ÿÿ_ÿÿÿÿ

!

`ÿÿ"ÿ ÿÿ*ÿ#
`s
`+ÿÿ8ÿ57ÿ,#0ÿÿÿ$ÿ%"ÿ57ÿ,4ÿ0ÿ##5ÿ*ÿ"ÿ ÿÿÿ3ÿ57ÿ,"
`0/ÿÿ
`# ÿ

!

`ÿÿ*ÿÿÿ`#ÿÿ"ÿ ÿÿ8ÿ57ÿ,#0ÿ#ÿaÿ5ÿ
`ÿ5ÿ

!

`ÿ5ÿÿÿ8ÿ57ÿÿÿÿ3ÿ57/
` ÿÿ:ÿ;ÿ

!

`ÿÿÿÿÿÿÿÿ5ÿ^#ÿ

ÿ##5 ÿ(#ÿ6#
`)ÿ #ÿ,(6) 0/ÿÿ_ÿÿÿÿ

!

`ÿÿ"ÿ ÿÿ*ÿ#ÿ+ÿÿ8
`57ÿ,#0/
`>?@ABCDECÿHDLGCMÿ>ELAB?DC>AEÿLABÿGMNGDÿOPQRSTUVTWXYÿ>EZGIC>AEÿ
`

!

`ÿ,[*0ÿ +ÿÿÿÿÿ5ÿ#ÿÿ#ÿÿÿ#
`r
`[ÿÿ75ÿÿÿ[*ÿÿÿÿÿÿÿÿ

!

`/
`s
` #ÿ+ÿ# ÿÿ5ÿ

!

`ÿÿ*ÿÿ5ÿ#ÿÿ#
`/ÿÿ2ÿÿ+ÿ`ÿÿ#5ÿ*ÿÿ5ÿ ÿ

!

`/ÿÿ2ÿ#
`*ÿÿÿÿÿÿ ÿÿ#ÿÿ#ÿÿ5ÿ#ÿÿ#
`*ÿ ÿ#/ÿ #ÿ[ÿÿ*ÿÿ ÿÿÿ#ÿÿÿ

!

`/
`
`ÿÿÿ#ÿÿÿ*ÿÿ5ÿÿÿÿ#ÿ+ÿ# ÿ5
`

!

`/ÿÿ;ÿÿÿ#ÿÿÿ#ÿ*ÿÿÿÿ#ÿ ÿ5
`)

<ÿ*/ÿÿ #ÿÿÿÿÿÿÿÿÿÿ#ÿ*ÿÿÿ 
`#/
`_ÿÿÿ#ÿ7ÿÿ#ÿ**#ÿÿ,
`_

0ÿ##5 ÿÿÿ#ÿ)

<ÿ*
`# ÿ

!

`ÿ$ÿÿ#ÿ7ÿ#ÿ#ÿÿÿ#ÿÿ,# ÿÿ
`75ÿ0/ÿÿ_ÿÿÿ
`_

ÿÿÿ)

\ÿ%ÿÿ)

\ÿ"ÿ5ÿ
`^=ÿÿÿÿÿ5ÿ

!

`
`5ÿ%/3ÿ ÿÿ$ÿ/ÿ_ÿÿÿ
`_

ÿÿÿ( 2

69 (:;ÿÿ
` 

ÿ(6) ÿÿ5ÿÿ
`ÿÿ5ÿ

!

`ÿÿ5ÿ%/8ÿÿÿ ÿÿ#ÿ ÿÿ$ÿÿ/ÿÿ
`_ÿÿÿÿÿ,&ÿÿ0ÿÿÿÿ ÿ

!

`ÿ5ÿ+#
` ÿÿÿÿÿÿÿ[ÿÿÿ#ÿ/
`;ÿÿÿ#ÿÿÿ+ÿÿÿÿÿ-.ÿ/%ÿÿ#ÿ+ÿ5
`

!

`ÿ# ÿ#ÿÿÿÿ#ÿÿÿÿ/
`2#ÿÿÿ##ÿ2* ÿ ÿÿ555

!

`/
`DSbcXÿXdTÿGMNGDÿOPQRSTUVTWXYÿ>efTVXRbeÿKgbSPgÿIbggPSbUPXRbeÿ
`6 ÿÿ##* ÿ5ÿ'ÿh#(ÿÿÿ #*#ÿ#ÿÿ

!

`/ÿÿ ÿiÿ"%%ÿ'
`r
`h#(ÿ*ÿÿ#ÿÿ7 ÿjÿÿ

ÿÿ#ÿ,50ÿ ]#ÿ#
` ÿ,5ÿ
`^=0/ÿÿ'ÿh#kÿiÿ*ÿ'ÿ!7ÿÿ*ÿÿ#ÿ
`7 ÿjÿÿÿ^ÿÿh#ÿ*ÿÿ\#ÿ,^h\0ÿÿ

!

`ÿÿÿÿÿ5
`
`^=/ÿ

!

`ÿÿÿ#ÿÿÿ
`#ÿ_ÿ ÿ
`ÿ,_
`0ÿÿÿÿ
`ÿ5ÿ5ÿ
`^=/ÿÿ_ÿ ÿÿ#ÿÿ7 ÿ#ÿÿ(#*ÿÿ5ÿ
`^=/
`'ÿh#(ÿ5##ÿ7ÿ

!

`ÿÿÿ:ÿ;ÿ5ÿÿÿ5##ÿÿ`##ÿÿ$
`ÿÿÿ#ÿÿ

!

`/ÿÿ6 ÿÿ#ÿ ÿÿ

!

`ÿÿÿ:ÿ;/
`DSbcXÿITeXUPgÿBTXRePgÿlTReÿAVVgcmRbeÿ
`
` ÿ%ÿ#ÿÿÿ:ÿ;ÿÿÿÿÿÿ(6) /ÿÿ(6) ÿÿÿ*ÿ*ÿÿ
`#ÿ#ÿÿÿ#ÿÿÿ*7ÿÿÿ*#ÿÿ[ÿÿÿ/ÿÿ_ÿÿ#ÿ ÿÿ#ÿ
`/ÿÿ6#ÿÿ#ÿ##ÿ 5ÿÿ,)

<0ÿ*ÿÿÿ#ÿ*#ÿÿ
`ÿÿ#ÿ/ÿÿ ÿÿ*#ÿÿ])

<ÿÿÿ#ÿÿ#ÿ*#ÿÿ
`ÿÿÿÿÿ5ÿ(6) /
`DSbcXÿBTnTeTUbeÿ@dPUoPVTcXRVPgmÿ
`6 ÿÿÿ##ÿ ÿ*#ÿÿÿÿÿ#ÿÿ
`#jÿÿÿÿÿÿÿ#ÿ/ÿÿ6 ÿ7ÿÿÿÿ
`:ÿ;ÿ

!

`ÿ,[*0ÿ +ÿp
`_6
`2ÿ,j][*0ÿ +ÿÿ ÿ ÿ
`
`6(
`!;_ÿ,#0ÿ +ÿÿ;*ÿ:qÿp
`_6
`2ÿÿ]#jÿ5ÿ;$/ÿÿ2ÿ4
`s
`s
`ÿÿÿ ÿ5ÿ

!

`ÿÿ5ÿ#ÿÿÿ5ÿÿÿ#*ÿ
`s
`
` 
`
`Exhibit 2252
`Page 02 of 03
`
`

`

`REGN727. Regeneron has active research and developmentprograms in manydiseaseareas,including
`ophthalmology,inflammation, cancer, and hypercholesterolemia. Additional information and recent newsreleases
`are available on the Regeneron website at www.regeneron.com.
`
`Forward Looking Statements
`This newsreleaseincludes forward-looking statements that involverisks and uncertainties relating to future events and
`the future performance of Regeneron, and actual events or results may differ materially from these forward-looking
`statements. These statements concern, and theserisks and uncertainties include, among others, the nature, timing,
`and possible success and therapeutic applications of Regeneron's products, product candidates and research and
`clinical programs now underwayorplanned, including withoutlimitation EYLEA® (aflibercept), unforeseen safety issues
`resulting from the administration of products and product candidatesin patients, the likelihood and timing of possible
`regulatory approval and commercial launch of Regeneron’s late-stage product candidates, determinations by regulatory
`and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or
`commercialize Regeneron's products and drug candidates, competing drugs that may be superior to Regeneron's
`products and drug candidates, uncertainty of market acceptance of Regeneron's products and drug candidates,
`unanticipated expenses,
`the costs of developing, producing, and selling products, the potential for any license or
`collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or
`terminated, and risks associated with third party intellectual property and pending orfuture litigation relating thereto. A
`more complete description of these and other materialrisks can be found in Regeneron's filings with the United States
`Securities and Exchange Commission, including its Form 10-K for the year ended December31, 2011 andits Form 10-Q
`for the quarter ended June 30, 2012. Regeneron doesnot undertake any obligation to update publicly any forward-
`looking statement, whether as a result of new information, future events, or otherwise, unless required by law.
`ContactInformation:
`Peter Dworkin
`Manisha Narasimhan, Ph.D.
`Corporate Communications
`Investor Relations
`914.847.7640
`914.847.5126
`
`Manishanarasimhan@reamneron.com Raterdworkin@reqsneron.com
`
`
`LEA-0108
`
`SOURCERegeneron Pharmaceuticals,Inc.
`
`NewsProvided by Acquire Media
`
`Exhibit 2252
`
`Page 03 of 03
`
`HA
`Mobis
`
`3/3
`
`Exhibit 2252
`Page 03 of 03
`
`